Sort
4,870 grants matching “glp 1”
Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome
$1,193,671Charles Testa · Curza Inc · R01 · FY2020 · AI
PERCUTANEOUS TREATMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE WITH IMPLANTATION OF MULTIPLE, BALLOON-EXPANDABLE, DRUG-ELUTING BIORESORBABLE SCAFFOLDS (the Efemoral Vascular Scaffold System)
$1,192,988Lewis Schwartz · Efemoral Medical, Inc. · R44 · FY2023 · HL
Rho GTPase inhibitor for refrigerated platelet storage
$1,188,244Brittany De Kouchkovsky · Ogb4 Inc · R44 · FY2024 · HL
Development of an anti-malaria toxin vaccine candidate
$1,186,750William J Christ · Ancora Pharmaceuticals, Inc. · R44 · FY2007 · AI
A Pan-Dengue Virus Immunotherapeutic for Prevention and Treatment
$1,185,525Leslie S Johnson · Macrogenics, Inc. · R01 · FY2013 · AI
Alzheimer's Disease Therapeutic
$1,183,503Trevor P. Castor · Aphios Corporation · R44 · FY2012 · AG
Novel compounds for the treatment of systemic sclerosis-associated interstitial lung disease
$1,182,632Scott Scarneo · Eydis Bio, Inc. · R44 · FY2024 · HL
Preclinical development of a vaccine for Nipah virus
$1,179,782Thomas William Geisbert · University Of Texas Med Br Galveston · R01 · FY2022 · AI
Development of a novel small molecule RPN13 inhibitor and therapeutic for advanced ovarian cancer patients
$1,178,998Ravi Kumar Anchoori · Up Therapeutics, Inc. · R44 · FY2024 · CA
Development of a Novel Lead Series Against Category A & B Bacterial Pathogens
$1,174,338Terry L Bowlin · Microbiotix, Inc · U01 · FY2012 · AI
Apical Access System with Universal Connector for Beating Heart LVAD Implantation
$1,173,971Jorge Hernan Jimenez · Apk Advanced Medical Technologies, Inc. · R44 · FY2015 · HL
cGMP manufacturing of PBI-220, a broad spectrum immunoadhesin therapeutic against
$1,166,055Lloyd M Yu · Planet Biotechnology, Inc. · R01 · FY2012 · AI
RBD recombinant protein-based SARS vaccine for biodefense
$1,165,855Peter J Hotez · Baylor College Of Medicine · R01 · FY2016 · AI
RBD recombinant protein-based SARS vaccine for biodefense
$1,165,726Peter J Hotez · Baylor College Of Medicine · R01 · FY2015 · AI
EVVS: Endoscopic Venous Valve System
$1,165,363Janet Galtes · Venarum Medical, Llc · R44 · FY2018 · HL
Development of PEGylated MTI-101 for the treatment of relapsed Myeloma
$1,161,570Rikki Noel Waterhouse · Modulation Therapeutics, Inc. · R44 · FY2018 · CA
Development of a potent and selective oral ENPP1 inhibitor for oncology
$1,160,011Mohan Rao Kaadige · Stingray Therapeutics, Inc. · R44 · FY2022 · CA
Preclinical and Clinical Evaluation of Humanized NM9405
$1,159,286Rekha Bansal · Novelmed Therapeutics, Inc. · R44 · FY2015 · HL
Preclinical development of a vaccine for Nipah virus
$1,159,045Thomas William Geisbert · University Of Texas Med Br Galveston · R01 · FY2023 · AI
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
$1,158,273Matthew Reed · Nob Hill Therapeutics, Inc. · R44 · FY2022 · HL
Preclinical development of a vaccine for Nipah virus
$1,157,701Thomas William Geisbert · University Of Texas Med Br Galveston · R01 · FY2025 · AI
Optimizing Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Malaria
$1,157,642David Waterson · Medicines For Malaria Venture · U01 · FY2011 · AI
PTE-based drug for antibiotic-resistant anthrax
$1,156,790Protez Pharmaceuticals, Inc. · U01 · FY2005 · AI
Suction Device for Control and Accuracy of Transseptal Access
$1,156,449Gregory S Kelley · 3dt Holdings, Llc · R44 · FY2018 · HL
Translating a CSF delivered AAV9-SMN for treatment of Spinal Muscular Atrophy
$1,155,044Brian K Kaspar · Research Inst Nationwide Children'S Hosp · U01 · FY2014 · NS